-
Inflammatory bowel disease: classifying global regions by epidemiological stage Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-13 Jordan Hindson
It has previously been proposed that the epidemiology of inflammatory bowel disease (IBD) in a region evolves predictably across four distinct epidemiological stages determined by changes in incidence and prevalence. The four stages are emergence, acceleration in incidence, compounding prevalence and prevalence equilibrium. Now, a new study published in Nature has applied this framework to real-world
-
Deep Visual Proteomics elucidates α1-antitrypsin deficiency Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-13 Jordan Hindson
In a new study published in Nature, researchers have investigated the progression of the genetic liver disease α1-antitrypsin deficiency (AATD) in human tissue. Spatial proteomics by mass spectrometry and machine learning, via a technique termed Deep Visual Proteomics, was able to analyse the progressive proteotoxicity of AATD, a condition that causes misfolding of α1-antitrypsin in hepatocytes. A
-
Gut-to-brain vagal afferents transmit reward signals Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-05-12 Kenny L. Chan
Although the gut–brain axis has long been thought to guide mood and behaviour, it had not been thoroughly investigated at a neurocircuit level until 2018, when a key paper by Han and colleagues delineated a gut-to-brain circuit stimulating reward behaviour. By mapping and manipulating the peripheral nervous system, the investigators found that sensory neurons in the nodose ganglion of the vagus nerve
-
Multicentre RCT of a self-assembling haemostatic gel to prevent delayed bleeding following EMR-an underpowered sample size calculation. Gut (IF 23.0) Pub Date : 2025-05-10 Eduardo Albéniz,Sheyla Montori
-
Gut microbiota drives structural variation of exogenous probiotics to enhance colonization. Gut Microbes (IF 12.2) Pub Date : 2025-05-10 Shuaiming Jiang,Shi Huang,Zeng Zhang,Wenyao Ma,Zhe Han,Yuan Song,Dongxue Huo,Weipeng Cui,Jiachao Zhang
Probiotics encounter colonization resistance from native gut microbiomes, affecting their effectiveness. Genetic engineering of probiotics lacks universal applicability, as gut microbiotas are highly individualized. Here, we employed probiotic Lactiplantibacillus plantarum HNU082 (Lp082) to test whether Lp082 gut-adapted mutants can resolve colonization resistance in a new gut environment. Relying
-
Beneficial infections of the enterovirus genus in patients with liver cancer Gut (IF 23.0) Pub Date : 2025-05-08 Lichun Ma, Man Hsin Hung, Farid Rashidi Mehrabadi, Limin Wang, Qin Li, Marshonna Forgues, Kathy Cheng Wang, Anuradha Budhu, Julián Candia, Jittiporn Chaisaingmongkol, Siritida Rabibhadana, Benjarath Pupacdi, Mathuros Ruchirawat, Xin Wei Wang
Background Hepatocellular carcinoma (HCC) is a significant global cancer burden, with rising incidence and lacking a unified prevention strategy due to complex aetiologies. Viral exposures may shape host immunity via specific reactive viral antigens that could induce immune responses against hepatocarcinogenesis. Objective We aimed to characterise viral exposure differences between HCC patients and
-
Microbial-derived peptidases are altered in celiac disease, non-celiac gluten sensitivity, and functional dyspepsia: a systematic review and re-analysis of the duodenal microbiome. Gut Microbes (IF 12.2) Pub Date : 2025-05-09 Jennifer C Pryor,Cheenie Nieva,Nicholas J Talley,Guy D Eslick,Kerith Duncanson,Grace L Burns,Emily C Hoedt,Simon Keely
Dietary gluten triggers symptoms in patients with gluten-related disorders (GRDs) including celiac disease (CeD), non-celiac gluten sensitivity (NCGS), and subsets of patients with functional dyspepsia (FD). The gastrointestinal microbiota is altered in these patients when compared to healthy individuals. As the microbiota is crucial for the hydrolysis of gluten, we hypothesized that the capacity of
-
Human milk oligosaccharide metabolism and antibiotic resistance in early gut colonizers: insights from bifidobacteria and lactobacilli in the maternal-infant microbiome. Gut Microbes (IF 12.2) Pub Date : 2025-05-09 Anna Samarra,Simone Renwick,Aleksandr A Arzamasov,Dmitry A Rodionov,Kennedy Spann,Raul Cabrera-Rubio,Antia Acuna-Gonzalez,Cecilia Martínez-Costa,Lindsay Hall,Nicola Segata,Andrei L Osterman,Lars Bode,MCarmen Collado
Breast milk, rich in human milk oligosaccharides (HMOs), supports the early-life colonization of beneficial bacteria such as bifidobacteria and lactobacilli, potentially reducing early-life antibiotic resistance. However, antibiotic treatment may interfere with the beneficial functions of HMO-degrading bacteria. This study investigated the metabolism of HMOs by bifidobacteria and lactobacilli isolated
-
Letter: Selective FGFR1c/KLB Activation in MASH—A Mechanistic Dilemma? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-09 Cuiyun Tao, Ye Liang, Jianghui Zeng
The Phase 2b trial of MK-3655 (NCT04583423) provides critical insights into fibroblast growth factor 21 (FGF21) pathway modulation, yet raises fundamental questions about therapeutic targeting strategies [1]. While the reported 26.1% placebo-adjusted liver fat reduction at 300 mg (p < 0.05) aligns with early-phase FGF21 analogs [2], it falls substantially below the ≥ 40% reductions seen with efruxifermin
-
Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-09 Maryam Irshad, Shahzeen Irshad
We read with interest the study by Ye et al. [1]. The authors demonstrated that targeted next-generation sequencing (tNGS) has high sensitivity (83%) and 100% specificity for detecting Mycobacterium tuberculosis from fresh ulcer base biopsy samples, offering an alternative to conventional methods like acid-fast bacillus staining, TB-PCR, and histopathological examination. Given the diagnostic challenges
-
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Nurulamin M Noor, Miles Parkes, Tim Raine
No Abstract
-
Retraction and republication—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08
In December, 2023, The Lancet Gastroenterology & Hepatology published the results of the DRA-GOO trial,1 comparing endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) versus uncovered duodenal metal stenting for patients with unresectable malignant gastric outlet obstruction.
-
Inclusion of patients with isolated ulcerative proctitis in clinical trials Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Andrew W Nguyen, Ashish R Srinivasan, Mark Lai, Tamar Schildkraut, Abhinav Vasudevan
No Abstract
-
The pitfalls and promises of scoping reviews in gastroenterology literature Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Morris Gordon
No Abstract
-
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Carrie Levinson, Shabari Shenoy, Manasi Agrawal
No Abstract
-
Research in Brief Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Holly Baker
Section snippets FIT screening non-inferior to colonoscopyFaecal immunochemical test (FIT) screening is more widely accepted than colonoscopy and offers non-inferior protection against colorectal cancer mortality, according to the 10-year results of the COLONPREV trial.Antoni Castells and colleagues randomly assigned participants to receive an invitation to one-time colonoscopy (n=28 708) or FIT every
-
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Remo Panaccione, Séverine Vermeire, Silvio Danese, Peter D R Higgins, Gary R Lichtenstein, Hiroshi Nakase, Sarah Glover, Jean-Frédéric Colombel, Jason Eccleston, Michelle Kujawski, Valencia Remple, Xuan Yao, Ziqian Geng, Hannah Palac, Dolly Sharma, Smitha Suravaram, Stefan Schreiber
BackgroundThe U-ACTIVATE long-term extension study aims to evaluate the long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis. Here, we report interim results after 3 years of total treatment. MethodsU-ACTIVATE is an ongoing, 288-week, phase 3, long-term extension study done at 307 centres across 43 countries (active sites on Dec 31, 2021, are
-
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Cihan Gani, Emmanouil Fokas, Bülent Polat, Oliver J Ott, Markus Diefenhardt, Alfred Königsrainer, Simon Böke, Andreas Kirschniak, Robert Bachmann, Dörte Wichmann, Michael Bitzer, Stephan Clasen, Ulrich Grosse, Rüdiger Hoffmann, Martin Götz, Ralf-Dieter Hofheinz, Elisabeth Germer, Christoph-Thomas Germer, Rainer Fietkau, Peter Martus, Claus Rödel
BackgroundTotal neoadjuvant therapy has been shown to increase pathological complete response and disease-free survival in patients with locally advanced rectal cancer after total mesorectal excision (TME). We hypothesised that total neoadjuvant therapy could maximise the number of patients attaining a clinical complete response who could then be instead referred to organ preservation with watch and
-
Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-05-08 Anthony Yuen Bun Teoh, Sundeep Lakhtakia, Ilaria Tarantino, Manuel Perez-Miranda, Rastislav Kunda, Fauze Maluf-Filho, Vinay Dhir, Jahangeer Basha, Shannon Melissa Chan, Dario Ligresti, Mark Tsz Wah Ma, Carlos de la Serna-Higuera, Hon Chi Yip, Enders Kwok Wai Ng, Philip Wai Yan Chiu, Takao Itoi
BackgroundEndoscopic ultrasonography-guided gastroenterostomy (EUS-GE) is a novel endoscopic method to palliate malignant gastric outlet obstruction. We aimed to assess whether the use of EUS-GE with a double balloon occluder for malignant gastric outlet obstruction could reduce the need for reintervention within 6 months compared with conventional duodenal stenting. MethodsThe was an international
-
Rifaximin Prophylaxis and “Collateral Damage” in Patients with Advanced Liver Disease Gastroenterology (IF 25.7) Pub Date : 2025-05-08 Henry F. Chambers, Cesar A. Arias
No Abstract
-
Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis Gut (IF 23.0) Pub Date : 2025-05-07 Virginia Mela, Violeta Heras, Monika Iesmantaite, María Luisa García-Martín, Manuel Bernal, Joel D Posligua-García, Alba Subiri-Verdugo, José Ignacio Martínez-Montoro, Ana María Gómez-Pérez, Borja Banderas, Isabel Moreno Indias, Francisco J Tinahones
Background Obesity-related cognitive decline is linked to gut microbiota dysbiosis, with emerging evidence suggesting that dietary interventions may ameliorate cognitive impairment via gut-brain axis modulation. The role of microglial cells in this process remains underexplored. Objective To investigate how diet-induced changes in gut microbiota influence cognitive function in individuals with obesity
-
Critical appraisal of the HELIOS study on surveillance in IBD patients Gut (IF 23.0) Pub Date : 2025-05-07 Shiwei Yang, Junning Liu, Guang Zhang
We read with great interest the recently published study by Groen et al comparing high-definition (HD) dye-based chromoendoscopy (CE) to HD white-light endoscopy (WLE) with segmental re-inspection and single-pass HD WLE in surveillance for colorectal neoplasia (CRN) in inflammatory bowel disease (IBD) patients.1 This multicentre randomised controlled trial addresses a critical clinical question. However
-
When getting reactive becomes the nORM: the emerging roles of proinflammatory cholangiokines Gut (IF 23.0) Pub Date : 2025-05-07 Yong He, Enis Kostallari
Liver diseases remain clinically challenging and exhibit complex cellular interactions, including liver cell–immune cell communications that can shape disease progression.1 During portal injury, biliary epithelial cells (BECs, also known as cholangiocytes) expand excessively, a process termed ‘ductular reaction (DR)’ which promotes fibrogenesis, tumourigenesis and consecutive liver disease progression
-
Engineered bacteria as an orally administered anti-viral treatment and immunization system. Gut Microbes (IF 12.2) Pub Date : 2025-05-08 Nitin S Kamble,Shindu Thomas,Tushar Madaan,Nadia Ehsani,Saqib Sange,Kiersten Tucker,Alexis Muhumure,Sarah Kunkler,Nalinikanth Kotagiri
The emergence of new viral pathogens necessitates innovative antiviral therapies and vaccines. Traditional approaches, such as monoclonal antibodies and vaccines, are often hindered by resistance, limited effectiveness, and high costs. Here, we develop an engineered probiotic-based antiviral platform using Escherichia coli Nissle 1917 (EcN), capable of providing both mucosal and systemic immunity via
-
Fusobacterium mortiferum and its metabolite 5-aminovaleric acid promote the development of colorectal cancer in obese individuals through Wnt/β-catenin pathway by DKK2. Gut Microbes (IF 12.2) Pub Date : 2025-05-08 Jiaxin Deng,Jiawei Zhang,Mingli Su,Juan Li,Yuping Su,Qinghua Zhong,Jiancong Hu,Yongcheng Chen,Sen Liao,Dezheng Lin,Xuefeng Guo
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, with high incidence and mortality rates. An increasing body of research suggests that obesity is a significant risk factor for the development of CRC. Moreover, recent findings have highlighted the close association between the gut microbiota and both obesity and CRC. Despite this, the specific mechanisms by which the gut microbiota
-
Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-08 Chachrit Khunsriraksakul, Olivia Ziegler, Dajiang Liu, Audrey S. Kulaylat, Matthew D. Coates
We appreciate the opportunity to respond to the comments submitted by Mao et al. [1] relating to our article [2]. They provided thoughtful commentary about the strengths and weaknesses of our study, and we agree with several concerns and recommendations that they shared. For example, they highlighted the potential limitations of relying upon ICD-10 codes to assess the abdominal pain status of each
-
Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-08 Haoxun Mao, Sheng Li
We appreciate the systematic evaluation of the effects of antispasmodics in patients with IBD by Dr. Khunsriraksakul and colleagues [1]. This addressed an important gap in our understanding of the effectiveness of antispasmodics in patients with IBD and has raised critical concerns for clinical practice. However, some aspects could be further refined to enhance clinical relevance. First, the definition
-
Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-08 Sarah Flatley, Selena Dixon, Eleanor Pilsworth, Asha Dube, Barbara Hoeroldt, Laura Harrison, Dermot Gleeson
-
Need for standardised approaches to human microbiome research using the example of colorectal neoplasia research Gut (IF 23.0) Pub Date : 2025-06-01 Sarah Manning, Rashmi Sinha, Colin J Rees
The role of the human microbiome in GI disease is an area of significant clinical and academic interest. The microbiome may well influence a number of GI diseases ranging from cancer,1 2 to IBD,3 4 to liver disease.5 6 One of the current challenges faced by microbiome researchers is the variance in terminology, methodological approaches and lack of consistency regarding outcomes. This is an issue that
-
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment Gut (IF 23.0) Pub Date : 2025-06-01 Romain Désert, Lipika Goyal, Thomas F Baumert
Cholangiocarcinoma (CCA) is a highly aggressive adenocarcinoma of the biliary tract system with unsatisfactory therapeutic options.1 Standard frontline treatment for unresectable or metastatic CCA consisting of cisplatin and gemcitabine combined with checkpoint inhibitors targeting programmed cell death ligand 1 or programmed cell death 1 offers objective response rates of less than 30% and a median
-
Detection of large flat colorectal lesions by artificial intelligence: a persistent weakness and blind spot Gut (IF 23.0) Pub Date : 2025-06-01 Douglas K Rex, John J Guardiola, Daniel von Renteln, Yuichi Mori, Prateek Sharma, Cesare Hassan
Computer-aided detection (CADe) has increased adenoma detection in randomised trials. However, unlike other detection adjuncts, CADe is lesion specific, that is, it is trained on a specific set of lesions. If the training does not include sufficient examples of precancerous lesion subsets, CADe may not perform adequately for lesions in that subset. In a prospective assessment of a second-generation
-
Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study Gut (IF 23.0) Pub Date : 2025-06-01 Ze-Rong Cai, Yong-Qiang Zheng, Yan Hu, Meng-Yao Ma, Yi-Jin Wu, Jia Liu, Lu-Ping Yang, Jia-Bo Zheng, Tian Tian, Pei-Shan Hu, Ze-Xian Liu, Lin Zhang, Rui-Hua Xu, Huai-Qiang Ju
Background and objective Gastric cancer (GC) remains a prevalent and preventable disease, yet accurate early diagnostic methods are lacking. Exosome non-coding RNAs (ncRNAs), a type of liquid biopsy, have emerged as promising diagnostic biomarkers for various tumours. This study aimed to identify a serum exosome ncRNA feature for enhancing GC diagnosis. Designs Serum exosomes from patients with GC
-
Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn’s disease Gut (IF 23.0) Pub Date : 2025-06-01 Daniela Guisado, Sayali Talware, Xiaoli Wang, Andrew Davis, Elbek Fozilov, Aaron Etra, Jean-Frederic Colombel, Christoph Schaniel, Christopher Tastad, John E Levine, James L M Ferrara, Chuang Ling-Shiang, Ksenija Sabic, Shishir Singh, Bridget K Marcellino, Ronald Hoffman, Judy Cho, Louis Cohen
Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain refractory to treatment. Autologous haematopoietic stem cell transplantation (SCT) is an emerging therapy for medically refractory CD though the mechanisms through which it circumvents refractory pathophysiology are unknown. Objective The objective of this study is to understand
-
Purified oat protein can trigger acute symptoms linked to immune activation in coeliac disease patients but not histological deterioration Gut (IF 23.0) Pub Date : 2025-06-01 Melinda Y Hardy, Amy K Russell, Lee M Henneken, Greg Tanner, Ferenc Bekes, Ian Brown, Allan Motyer, Sam W Z Olechnowicz, Hugh H Reid, Jamie Rossjohn, Jason A Tye-Din
Background Oat ingestion in coeliac disease (CD) is generally regarded as safe but can trigger enteropathy and T cells specific for oat avenin in the gut and blood of some individuals. Objective To correlate immune and clinical outcomes to oats, purified avenin and oat feeding studies were performed to examine symptoms, T-cell immunity and intestinal histology in CD. Design 33 treated HLA-DQ2.5+ adult CD
-
Serological screening for coeliac disease in an adult general population: the HUNT study Gut (IF 23.0) Pub Date : 2025-06-01 Ina Lervåg Andersen, Polina Lukina, Ole T Dyrli, Rolf Anton Klaasen, David John Warren, Nils Bolstad, Patricia Mjønes, Elin Rønne, Rasmus Iversen, Ludvig M Sollid, Knut E A Lundin, Eivind Ness-Jensen
Background A large proportion of individuals with coeliac disease (CeD) remain undiagnosed. Objective The aim of this study was to assess serological screening for CeD in the adult general population. Design The study was based on the fourth Trøndelag Health Study, a population-based study performed 2017–2019 in Nord-Trøndelag County, Norway, including 56 042 participants >20 years of age (54% participation
-
Carbon footprinting and environmental impact of gastrointestinal endoscopy procedures at a tertiary care institution: a prospective multi-dimensional assessment Gut (IF 23.0) Pub Date : 2025-06-01 Hardik Rughwani, Rakesh Kalapala, Anudeep Katrevula, Nitin Jagtap, Madhav Desai, Sara Teles de Campos, Mohan Ramchandani, Sundeep Lakhtakia, Rupjyoti Talukdar, Santosh Darisetty, Sana Fatima Memon, Guduru Venkat Rao, Marco Bruno, Prateek Sharma, D Nageshwar Reddy
Background Given the imperative to combat climate change, reducing the healthcare sector’s implications on the environment is crucial. Objective This study aims to offer a comprehensive assessment of the environmental impact of gastrointestinal endoscopy (GIE) procedures, specifically focusing on greenhouse gas (GHG) emissions and waste generation. Design A prospective study was conducted at the Asian
-
Dysbiotic oral microbiota-derived kynurenine, induced by chronic restraint stress, promotes head and neck squamous cell carcinoma by enhancing CD8+ T cell exhaustion Gut (IF 23.0) Pub Date : 2025-06-01 Fangzhi Lou, Li Yan, Shihong Luo, Yunmei Dong, Jingyi Xu, Ning Kang, Haiyang Wang, Yiyun Liu, Juncai Pu, Bing Yang, Richard D Cannon, Peng Xie, Ping Ji, Xin Jin
Background Chronic restraint stress (CRS) is a tumour-promoting factor. However, the underlying mechanism is unknown. Objective We aimed to investigate whether CRS promotes head and neck squamous cell carcinoma (HNSCC) by altering the oral microbiota and related metabolites and whether kynurenine (Kyn) promotes HNSCC by modulating CD8+ T cells. Design 4-nitroquinoline-1-oxide (4NQO)-treated mice were
-
Trends and cross-country inequality in the incidence of GI cancers among the working-age population from 1990 to 2021: a Global Burden of Disease 2021 analysis Gut (IF 23.0) Pub Date : 2025-06-01 Yiming Song, Xiaoyi Wang, Yufeng Shen, Liping Chen, Liuyi Yang, Ruilan Wang, Junyu Lu, Zhifang Gao, Xiaolu Lin, Yan Song, Qingwei Zhang, Xiaobo Li
Background GI cancers pose an increasing global health burden, with their impact on the working-age population (WAP) aged 15–64 years remaining largely unexplored despite the crucial role of this group in societal and economic well-being. Objective To assess trends and cross-country inequality in the global burden of six GI cancers from 1990 to 2021 among individuals in the WAP. Design The 2021 Global
-
Early detection of colorectal cancer using aberrant circulating cell-free mitochondrial DNA fragmentomics Gut (IF 23.0) Pub Date : 2025-06-01 Siyuan Wang, Fan Peng, Miao Dang, Huanmin Jiao, Huanqin Zhang, Kaixiang Zhou, Wenjie Guo, Zhiyun Gong, Lin Guo, Renquan Lu, Deliang Li, Bingrong Liu, Xu Guo, Jinliang Xing, Yang Liu
Background Early detection of colorectal cancer (CRC) is crucial for improving the survival rates of patients. Objective We aimed to develop a novel strategy for early CRC detection using the fragmentomic features of circulating cell-free mitochondrial DNA (ccf-mtDNA). Design Here, a total of 1147 participants, including 478 healthy controls (HCs), 112 patients with advanced adenomas (AAs) and 557
-
Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance: a prospective longitudinal cohort study Gut (IF 23.0) Pub Date : 2025-06-01 Tsuyoshi Hamada, Hiroki Oyama, Daniel Nevo, Shuichi Tange, Shinya Takaoka, Yoshikuni Kawaguchi, Kazunaga Ishigaki, Kensaku Noguchi, Tomotaka Saito, Tatsuya Sato, Tatsunori Suzuki, Naminatsu Takahara, Mariko Tanaka, Kiyoshi Hasegawa, Tetsuo Ushiku, Yousuke Nakai, Maxim S Petrov, Mitsuhiro Fujishiro
Background Cyst size, its growth rate, and diameter of the main pancreatic duct (MPD) are all associated with pancreatic carcinoma prevalence in intraductal papillary mucinous neoplasms (IPMNs). Objective To examine the above factors in relation to future risk of incident pancreatic carcinoma in individuals with IPMNs harbouring no high-risk stigmata. Design In a prospective longitudinal cohort, we
-
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab Gut (IF 23.0) Pub Date : 2025-06-01 Yuta Myojin, Sepideh Babaei, Rajiv Trehan, Christoph Hoffman, Noemi Kedei, Benjamin Ruf, Mohamed-Reda Benmebarek, Kylynda C Bauer, Patrick Huang, Chi Ma, Cecilia Monge, Changqing Xie, Donna Hrones, Austin G Duffy, Paul Armstrong, Lorenz Kocheise, Fiona Desmond, Jemma Buchalter, Marie Galligan, Colin Cantwell, Ronan Ryan, Jeff McCann, Michele Bourke, Ross Mac Nicholas, Ray McDermott, Joy Awosika, Maggie
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective To study immune responses in HCC patients treated with tremelimumab and durvalumab. Design We treated 28 HCC patients with durvalumab, tremelimumab and locoregional therapies. We performed a high-dimensional
-
Understanding tissue injury and remodelling in eosinophilic oesophagitis: development towards personalised medicine Gut (IF 23.0) Pub Date : 2025-06-01 Giovanni Santacroce, Carlo Maria Rossi, Marco Vincenzo Lenti, Subrata Ghosh, Marietta Iacucci, Antonio Di Sabatino
Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated condition characterised by eosinophilic infiltration of the oesophagus, leading to significant morbidity due to oesophageal dysfunction. The pathogenic course of EoE begins with tissue injury, marked by the intricate interplay of oesophageal barrier dysfunction and T helper 2-mediated inflammation. In response to tissue damage, a subsequent
-
Vasomics of the liver Gut (IF 23.0) Pub Date : 2025-06-01 Chengyan Wang, Eric Felli, Jonathan Andrew Fallowfield, Christoph Frank Dietrich, Don Rockey, Jürgen Hennig, Gao-Jun Teng, Jordi Gracia-Sancho, Xiaolong Qi
Chronic liver disease is a cluster of disorders associated with complex haemodynamic alterations, which is characterised by structural and functional disruptions of the intrahepatic and extrahepatic vasculature. ‘Vasomics’ is an emerging omics discipline that comprehensively analyses and models the vascular system by integrating pathophysiology of disease, biomechanics, medical imaging, computational
-
Sphincterotomy with FCSEMS (SPHINX): a monumental answer or the beginning of new mysteries? Gut (IF 23.0) Pub Date : 2025-06-01 Mohan Ramchandani, Aniruddha Pratap Singh, Rupjyoti Talukdar, D Nageshwar Reddy
We read with interest the recently published randomised controlled trial (RCT) ‘SPHINX’,1 addressing the role of endoscopic sphincterotomy (ES) with fully covered s metal stent (FCSEMS) placement in preventing post-ERCP pancreatitis (PEP). Although this is the largest RCT on the topic, several concerns warrant discussion. Published data report variable rates of PEP after SEMS ranging from 0% to 26
-
Are histamine-2 receptor antagonists a reasonable comparator: comparing apples and apples? Gut (IF 23.0) Pub Date : 2025-06-01 Lizhi Hu, Yu Peng
We recently read with great interest the article by Devin Abrahami et al .1 We would like to raise some concerns that warrant further discussion. The association between proton pump inhibitors (PPIs) and the risk of inflammatory bowel disease (IBD) remains a debate, the authors mostly focus on the protopathic bias introduced by study design. However, in this study, the authors used histamine-2 receptor
-
Redefining QUAIDE: paving the way for better AI in preclinical endoscopy Gut (IF 23.0) Pub Date : 2025-06-01 Hui Li, Tiantian Zhang, Qin Guo, Shufen Zhou, Chengshan Guo
We read with great interest the recent article by Antonelli et al 1 on the quality assessment for artificial intelligence in digestive endoscopy (QUAIDE) framework, which enhances the quality and reproducibility of artificial intelligence (AI)-based gastrointestinal endoscopy research. While QUAIDE provides a solid foundation for pre-clinical research design, we see opportunities for further improvement
-
Colonic motility investigation by modern techniques: time to ‘reclaim’ the value of physiology? Gut (IF 23.0) Pub Date : 2025-06-01 Gabrio Bassotti
I read with interest the recent article of Wilkinson-Smith and colleagues on the assessment of colonic motility by means of MRI and high-resolution colonic manometry (HRCM),1 showing that patients with constipation and irritable bowel syndrome (IBS) may display some abnormalities when such investigated. I would like to make some observations on this study. Since HRCM probes were positioned 35 cm from
-
SPHINX, a Guardian of Wisdom Gut (IF 23.0) Pub Date : 2025-06-01 Anke Onnekink, Roy L J van Wanrooij, Jeanin E Van Hooft
We thank Ramchandani et al for their letter on the SPHINX trial and appreciate the opportunity to address their points.1 2 The SPHINX trial aimed to assess whether endoscopic sphincterotomy (ES) could reduce post-ERCP pancreatitis (PEP). However, quantifying this effect proved difficult due to conflicting results from previous, heterogeneous randomised controlled trials (RCTs), which differed in sample
-
Frequency of de novo PRSS1 pathogenic variants in a French cohort of idiopathic pancreatitis Gut (IF 23.0) Pub Date : 2025-06-01 Emmanuelle Masson, Anne-Laure Vedie, Frédérique Maire, Tiphaine Godet, Louis Buscail, Vinciane Rebours, Claude Férec, Jian-Min Chen
We read with great interest the recent publication by Lou et al ,1 which addressed the challenge of false positives in next-generation sequencing (NGS) due to highly homologous PRSS1 paralogs.2 3 PRSS1 was the first gene linked to chronic pancreatitis,4 with p.Arg122His (c.365G>A) and p.Asn29Ile (c.86A>T) being the most common mutations associated with the Mendelian form of the disease. Accurate identification
-
Global health inequalities in the burden of gastrointestinal cancers from 1990 to 2021 Gut (IF 23.0) Pub Date : 2025-06-01 Chunlong Liu, Ziqiang He, Jiangtao Yu, Rui Yang
We read with great interest the study by Danpanichkul et al ,1 which assessed the global burden of gastrointestinal cancers, including oesophagus, gastric, colorectal, liver, pancreas and biliary tract cancers, from 2000 to 2021. The study revealed that the burden of all types of cancers varies across geographical and socioeconomic levels. The incidence rates of some types of gastrointestinal cancer
-
Revisiting the role of sphincterotomy in sphincter of Oddi disorder: a critical appraisal of the RESPOnD study Gut (IF 23.0) Pub Date : 2025-06-01 Xuefan Zeng
We read with great interest the article by Coté et al titled ‘Sphincterotomy for biliary sphincter of Oddi disorder and idiopathic acute recurrent pancreatitis: the RESPOnD longitudinal cohort’ published in Gut.1 The study aimed to measure the benefit of sphincterotomy for suspected sphincter of Oddi disorder (SOD) and provided valuable insights into the management of this contentious condition. While
-
Response to: correspondence on ‘Revisiting the role of sphincterotomy in sphincter of Oddi disorder: a critical appraisal of the RESPOnD study’ by Zeng Gut (IF 23.0) Pub Date : 2025-06-01 Gregory A Cote
Thanks to Dr Zeng for his insightful comments1 about our recent publication on 12-month outcomes of endoscopic retrograde cholangiopancreatography (ERCP) for sphincterotomy for sphincter of Oddi disorders (SOD).2 Many of the comments were addressed in the discussion of the paper, especially the significance of the unmeasured placebo response and greater importance of patient characteristics such as
-
GI snapshot: arrhythmia, dysphagia and weight loss in a 71-year-old man Gut (IF 23.0) Pub Date : 2025-06-01 Martina De Siena, Loredana Gualtieri, Simone Varca, Maria Valeria Matteo, Valerio Pontecorvi, Vincenzo Bove, Cristiano Spada, Ivo Boškoski
A 71-year-old man presented with a 2-months history of arrhythmia of undetermined cause, dysphagia, vomiting and 10 kg weight loss. The patient’s history was unremarkable except for multinodular goitre and hypertension. Laboratory exams did not demonstrate significant alterations, white cell count was 7.8×109/L (ref range: 4.0–10.0), haemoglobin 16.2 g/L (ref range: 12.0–15.0), platelet 281×109/L (ref
-
Distinct gut microbiota and metabolome features of tissue-specific insulin resistance in overweight and obesity. Gut Microbes (IF 12.2) Pub Date : 2025-05-07 Kelly M Jardon,Alexander Umanets,Anouk Gijbels,Inez Trouwborst,Gabby B Hul,Els Siebelink,Lars M M Vliex,Jacco J A J Bastings,Rosa Argamasilla,Elodie Chenal,Koen Venema,Lydia A Afman,Gijs H Goossens,Ellen E Blaak
Insulin resistance (IR) is an early marker of cardiometabolic deterioration which may develop heterogeneously in key metabolic organs, including the liver (LIR) and skeletal muscle (MIR). This tissue-specific IR is characterized by distinct metabolic signatures, but the role of the gut microbiota in its etiology remains unclear. Here, we profiled the gut microbiota, its metabolites and the plasma metabolome
-
Novel cross-feeding human gut microbes metabolizing tryptophan to indole-3-propionate. Gut Microbes (IF 12.2) Pub Date : 2025-05-07 Janina N Zünd,Denisa Mujezinovic,Markus Reichlin,Serafina Plüss,Marina Caflisch,Serina Robinson,Christophe Lacroix,Benoit Pugin
Tryptophan-derived indoles produced by the gut microbiota, particularly indole-3-propionate (IPA), are key compounds associated with gastrointestinal balance and overall health. Reduced levels of IPA have been associated with inflammatory bowel disease, type 2 diabetes, and colorectal cancer. Since fiber-rich diets have been shown to promote IPA, we aimed to decipher fiber-specific effects and identify
-
Indole signaling in Escherichia coli: a target for antivirulence therapy? Gut Microbes (IF 12.2) Pub Date : 2025-05-07 Sofia Razzaq Meo,Tom Van de Wiele,Tom Defoirdt
Pathogenic Escherichia coli are a major cause of infections in both humans and animals, leading to conditions such as severe diarrheal diseases, urinary tract infections, enteritis, and septicemia. To combat bacterial infections, antibiotics are widely utilized. However, the extensive and inappropriate use of antibiotics has fueled the development and spread of antibiotic resistance, posing a significant
-
Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-07 Kim W. E. Sweerts, Zlatan Mujagic, Daniel Keszthelyi, José M. Conchillo
We appreciate the interest and comments of Dr. Green and colleagues on our article about antroduodenal motility in patients with hypermobility spectrum disorders/hypermobile Ehlers–Danlos syndrome (HSD/hEDS) [1, 2]. They commented on the high frequency of food intolerance in the HSD/hEDS population resulting in a high prevalence of enteral and parenteral feeding, and the possible role of enteric dysmotility
-
Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehlers‐Danlos Syndrome? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-07 Caitlin Green, Anne Maitland, Steven A. Kautz, Russell Norris, Sunil Patel, Amol Sharma
We commend Sweerts et al. for their largest-to-date investigation using antroduodenal manometry (ADM) in 50 patients with hypermobility spectrum disorders (HSD) and hypermobile Ehler-Danlos Syndrome (hEDS) compared to 189 non-HSD/hEDS patients [1]. ADM, a labour-intensive and technically challenging procedure, comes the closest to the gold standard of histopathological evaluation of full-thickness
-
The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-05-07 Olga M. Nardone, Nurulamin M. Noor, Aniruddh Prabhu, Alessandra Lim, Anirudh Krishnakumar, Abdulaziz Alajmi, Yuhong Yuan, Vipul Jairath, Maria Manuela Estevinho, Virginia Solitano
-
Defining enteric bacterial pathogenesis using organoids: Citrobacter rodentium uses EspC, an atypical mucinolytic protease, to penetrate mouse colonic mucus. Gut Microbes (IF 12.2) Pub Date : 2025-05-05 Yan Chen,Ashley Gilliland,Qiaochu Liang,Xiao Han,Hyungjun Yang,Jocelyn Chan,Dominique Lévesque,Kyung-Mee Moon,Parandis Daneshgar,François-Michel Boisvert,Leonard Foster,Wesley F Zandberg,Kirk Bergstrom,Hong B Yu,Bruce A Vallance
Enteric bacterial pathogens pose significant threats to human health; however, the mechanisms by which they infect the mammalian gut in the face of daunting host defenses remain to be fully defined. For the attaching and effacing (A/E) bacterial family member and murine pathogen Citrobacter rodentium, its virulence strategy appears to involve penetration of the colonic mucus barrier to reach the underlying